

# A new European network for influenza vaccine effectiveness studies

**Topi Turunen**


22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

Vaccines are the cornerstone of preventing influenza  
but their effectiveness varies.



Annual **vaccine effectiveness studies** are needed.

## Multiple types of influenza vaccines on the market (and more on the way)





(trivalent, quadrivalent, live attenuated, high-dose,  
adjuvanted, cell-based ...)

Since 2017, the European Medicines Agency requires **brand-specific** influenza vaccine effectiveness results from manufacturers.

## EMA encourages industry to

*liaise with public health authorities who have experience in influenza effectiveness studies and who have implemented a functioning infrastructure to conduct multicentre studies*





# DRIVE

Development of Robust  
and Innovative Vaccine  
Effectiveness

is a public-private partnership launched by the Innovative Medicines Initiative in 2017 to establish:

**A sustainable study network** for brand-specific influenza vaccine effectiveness studies in the EU

**A governance model** for transparent, scientifically robust public-private partnerships

